Tirzepatide is a GIP and GLP-1 receptor agonist. SURMOUNT-1 investigated it in adults with obesity or overweight without diabetes under a defined clinical protocol.
Also referenced as: tirzepatide research · SURMOUNT-1 · GIP and GLP-1 receptor agonist.
Read efficacy and adverse events together; do not turn separate trials into a head-to-head comparison.
Research source & evidence
Tirzepatide Once Weekly for the Treatment of Obesity
The New England Journal of Medicine, 2022 · Randomized clinical trial in adults
The SURMOUNT-1 trial studied tirzepatide for weight management in adults without diabetes.
What this does not establish
Results apply to the trial population and protocol, not every group or product.
Tirzepatide questions
What is tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. The linked SURMOUNT-1 trial is a clinical research source, not a verification of research-market products.
How does tirzepatide work?
Tirzepatide acts at GIP and GLP-1 receptors. That mechanism is context for reading the clinical literature, not advice about personal use.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist, while tirzepatide acts at GIP and GLP-1 receptors. STEP 1 and SURMOUNT-1 are separate trials and cannot alone establish a head-to-head treatment ranking.
Does SURMOUNT-1 establish safety for all tirzepatide products?
No. Trial outcomes and adverse-event findings apply to the studied material, protocol, and population. They cannot authenticate or establish the safety of research-market products.
Source transparency
AI-assisted research summary based on the linked publication. This is not an independent systematic review or medical review. No named clinical reviewer or independent product verification is claimed. Publication year is the source’s year, not a promise that the evidence is current or complete.
No active affiliate links. Directory listings are not endorsements; research headlines are not clinical evidence.